Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata Appoints Jayant Chauhan as Chief Financial Officer17.6.2026 22:30:00 CEST | Press release
Brings More Than Two Decades of Experience in Finance and Scaling High-Growth Technology Companies, Effective July 6, 2026 Interim CFO Marissa Espineli to Transition to Chief Accounting Officer NEW YORK, NY / ACCESS Newswire / June 17, 2026 / INNODATA INC. (Nasdaq:INOD) ("Innodata" or the "Company") today announced that it has appointed Jayant Chauhan as Executive Vice President and Chief Financial Officer (CFO), effective July 6, 2026. At that time, Marissa Espineli, who is serving as the Company's Interim Chief Financial Officer, will transition to the new role of Chief Accounting Officer, reporting to Mr. Chauhan. Mr. Chauhan brings to Innodata more than two decades of experience building and leading finance functions for fast-growing global technology companies. He most recently served as Senior Vice President, M&A at Mphasis, a Blackstone-owned, publicly traded global IT services company, and previously as Senior Vice President, Global Strategic Finance, and CFO of the operated ho
Qualitest Becomes QualityAI: The Trusted Assurance and Engineering Partner Across Every Stage of Enterprise AI17.6.2026 18:45:00 CEST | Press release
As businesses double down on AI deployment, QualityAI helps enterprise leaders move beyond AI claims and go live with confidence. LONDON, UK / ACCESS Newswire / June 17, 2026 / Qualitest, the leading provider of AI-first quality engineering and assurance, today announces its rebrand to QualityAI. The new brand reflects the company's evolution from software testing specialist to AI-first quality engineering partner, helping enterprises design quality into complex systems from the outset. Across every industry, companies are racing to adopt AI, and the pressure to demonstrate progress is rising. According to Deloitte's 2026 "State of AI in the Enterprise" report, the proportion of organizations expecting at least 40% of AI experiments to reach production is expected to more than double within six months. As AI moves from ambition to implementation, leaders need to prove that transformation is real, reliable, and effective. In a market crowded with AI claims, assurance is becoming the dif
Skymantics Europe Joins BDVA to Overcome Data Scarcity Barriers in European AI Adoption17.6.2026 14:35:00 CEST | Press release
Providing fully GDPR-compliant synthetic population datasets to unlock paralyzed AI initiatives in Europe. ZARAGOZA, ES / ACCESS Newswire / June 17, 2026 / Skymantics Europe, developer of the DataGenesis™ AI software, today announced it has joined the Big Data Value Association (BDVA). This membership marks a pivotal step in Skymantics Europe's mission to help overcome one of the major barriers to European AI adoption, namely "data scarcity": availability of large quantities of high-quality data, compliant with GDPR and European AI Act. As European governments and businesses accelerate the AI adoption for complex decision-support environments, they face a recurring "Compliance Paradox": the need for high-fidelity data to drive innovation versus the legal requirement to protect citizen privacy. Skymantics Europe resolves this tension via DataGenesis™, its proprietary software engine that generates behavioral digital twins mathematically indistinguishable from production datasets, yet co
Crestone Air Partners, an Air T Business, Completes Acquisition of Arena Aviation Capital, Surpassing $3.6 Billion in Assets Under Management16.6.2026 23:10:00 CEST | Press release
Milestone reflects Air T's permanent-capital, buy-to-build model and the momentum of its networked aviation portfolio MINNEAPOLIS, MN / ACCESS Newswire / June 16, 2026 / Air T, Inc. (NASDAQ:AIRT) today announced that its majority owned business Crestone Air Partners, a global aviation asset management platform, has completed its acquisition of Arena Aviation Capital - a well-established aviation asset manager with a diversified portfolio and deep airline relationships. The transaction, first disclosed on March 8, 2026, has now closed following the satisfaction of all customary closing conditions and required approvals. The acquisition materially expands Crestone. Assets under management (AUM) as of December 31, 2025, were $800 million; as of March 31, 2026, AUM had grown to $1.2 billion; and post-transaction, the combined platform now comprises $3.6 billion of AUM. Crestone receives standard aviation industry management fees, including origination fees, administrative fees, disposition
On Sale Now! LiberNovo Maxis Big & Tall Ergonomic Chair Debuts, Unlocking a New Level of "Stability, Width, and Comfort" for Prolonged Sitting16.6.2026 18:00:00 CEST | Press release
The Maxis series is live today across the US, Canada, and Europe, starting at €829, with launch savings up to 48% off MSRP. HONG KONG, HK / ACCESS Newswire / June 16, 2026 / LiberNovo's Maxis series goes on sale today, the brand's first line built from the ground up for Big & Tall users rather than scaled up from a standard chair. It ships in three configurations, alongside two additions to the LiberNovo Omni family. Built for the body, not scaled up to fit Maxis targets the three things that fail a larger body in a standard seat: thighs left unsupported, a recline that sways under weight, and support that gives out by mid-afternoon. The 52 cm seat extends fully under the thigh. Multi-density foam holds its shape instead of bottoming out under load. A tall backrest and adjustable neck support hold the spine and neck, with the neck support sitting at the neck rather than behind the head. The frame is BIFMA-certified to 181 kg (399 lb) on a die-cast aluminum alloy base. Recline that hold
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom